{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:10:13Z","timestamp":1776276613584,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016957","name":"Mirati Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.lungcan.2024.107854","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T19:33:17Z","timestamp":1718220797000},"page":"107854","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Brain metastases in clinical trial participants with KRAS-mutated advanced non-small cell lung cancer receiving docetaxel: Pooled data analysis"],"prefix":"10.1016","volume":"193","author":[{"given":"Jacob","family":"Aptekar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8848-658X","authenticated-orcid":false,"given":"Rahul","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Korytowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2572-5521","authenticated-orcid":false,"given":"Afrah","family":"Shafquat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0284-520X","authenticated-orcid":false,"given":"Jacob","family":"Hendershot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4349-5928","authenticated-orcid":false,"given":"Aniketh","family":"Talwai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7373-8224","authenticated-orcid":false,"given":"Yahav","family":"Itzkovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8691-7754","authenticated-orcid":false,"given":"Sukhmani K.","family":"Padda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2024.107854_b0005","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.lungcan.2024.107854_b0010","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.jtho.2023.06.017","article-title":"Genomic alterations and the incidence of brain metastases in advanced and metastatic NSCLC: a systematic review and meta-analysis","volume":"18","author":"Gillespie","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2024.107854_b0015","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/oncolo\/oyac094","article-title":"Clinicopathologic and genomic landscape of non-small cell lung cancer brain metastases","volume":"27","author":"Huang","year":"2022","journal-title":"Oncologist."},{"key":"10.1016\/j.lungcan.2024.107854_b0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.lungcan.2022.05.004","article-title":"Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome","volume":"169","author":"Mogenet","year":"2022","journal-title":"Lung. Cancer."},{"key":"10.1016\/j.lungcan.2024.107854_b0025","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ejca.2021.10.006","article-title":"Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations","volume":"159","author":"Vassella","year":"2021","journal-title":"Eur. J. Cancer."},{"key":"10.1016\/j.lungcan.2024.107854_b0030","article-title":"Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion","volume":"2018","author":"Farago","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.lungcan.2024.107854_b0035","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41571-023-00808-4","article-title":"Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer","volume":"20","author":"Pan","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2024.107854_b0040","first-page":"171","article-title":"Prognostic significance of EGFR and KRAS mutations in NSCLC patients with brain metastases treated with radiosurgery(\u2020)","volume":"3","author":"Parikh","year":"2015","journal-title":"J. Radiosurg. SBRT."},{"key":"10.1016\/j.lungcan.2024.107854_b0045","doi-asserted-by":"crossref","first-page":"9088","DOI":"10.1200\/JCO.2021.39.15_suppl.9088","article-title":"Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer","volume":"39","author":"Arbour","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2024.107854_b0050","doi-asserted-by":"crossref","first-page":"9596","DOI":"10.1200\/JCO.2020.38.15_suppl.9596","article-title":"Clinical characteristics and anti-PD-(L)1 treatment outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer","volume":"38","author":"Arbour","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2024.107854_b0055","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished efficacy of programmed death-(ligand) 1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2024.107854_b0060","doi-asserted-by":"crossref","first-page":"18174","DOI":"10.1038\/s41598-021-97566-z","article-title":"Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases","volume":"11","author":"Lauko","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2024.107854_b0065","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.3390\/ijms17122132","article-title":"EGFR and KRAS mutations predict the incidence and outcome of brain metastases in non-small cell lung cancer","volume":"17","author":"Tomasini","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lungcan.2024.107854_b0070","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet."},{"key":"10.1016\/j.lungcan.2024.107854_b0075","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2024.107854_b0080","article-title":"Clinical trial eligibility criteria and recently approved cancer therapies for patients with brain metastases","volume":"11","author":"Tan","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2024.107854_b0085","doi-asserted-by":"crossref","first-page":"LBA9016","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9016","article-title":"Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): practice-informing data from a global, phase 3, randomized, controlled trial (RCT)","volume":"41","author":"Dingemans","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2024.107854_b0090","first-page":"JCO2300046","article-title":"Intracranial efficacy of adagrasib in patients from the KRYSTAL-1 trial with KRASG12C-mutated non-small-cell lung cancer who have untreated CNS metastases","author":"Negrao","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2024.107854_b0095","unstructured":"Medidata Solutions, Data Fabric Architecture of Medidata Clinical Cloud. https:\/\/www.medidata.com\/en\/clinical-trial-products\/unified-platform\/data-fabric\/, 2023 (accessed 12 October 2023)."},{"key":"10.1016\/j.lungcan.2024.107854_b0100","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2017.3438","article-title":"Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: the SELECT-1 randomized clinical trial","volume":"317","author":"J\u00e4nne","year":"2017","journal-title":"JAMA."},{"key":"10.1016\/j.lungcan.2024.107854_b0105","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/01.cad.0000136882.19552.8f","article-title":"Limited cerebrospinal fluid penetration of docetaxel","volume":"15","author":"ten Tije","year":"2004","journal-title":"Anti-Cancer. Drugs."},{"key":"10.1016\/j.lungcan.2024.107854_b0110","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.21037\/tlcr-20-1263","article-title":"Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study","volume":"10","author":"Matsumoto","year":"2021","journal-title":"Transl. Lung. Cancer. Res."},{"key":"10.1016\/j.lungcan.2024.107854_b0115","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/oncolo\/oyad013","article-title":"Ramucirumab plus docetaxel for patient with non-small cell lung cancer with brain metastases: a mutlticenter, open-label single-arm phase II trial","volume":"28","author":"Tanimura","year":"2023","journal-title":"Oncologist."},{"key":"10.1016\/j.lungcan.2024.107854_b0120","doi-asserted-by":"crossref","first-page":"TPS9129","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS9129","article-title":"KRYSTAL-12: a randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRASG12C mutation","volume":"39","author":"Mok","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2024.107854_b0125","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2024.107854_b0130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/B978-0-12-811161-1.00007-4","article-title":"Brain metastases: neuroimaging","volume":"149","author":"Pope","year":"2018","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.lungcan.2024.107854_b0135","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022400388X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022400388X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T05:35:59Z","timestamp":1727242559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022400388X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":27,"alternative-id":["S016950022400388X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107854","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brain metastases in clinical trial participants with KRAS-mutated advanced non-small cell lung cancer receiving docetaxel: Pooled data analysis","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107854","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107854"}}